These results suggest that administration of INH for less than six months may be as effective as longer courses of prophylaxis among non-HIV infected children.

Enrollment in CHAPTER-3, a Phase 3 study of deucrictibant for prophylaxis of HAE attacks, is progressing as planned, indicating ongoing commitment to advancing clinical development.

Isoniazid prophylaxis reduces the risk of developing tuberculosis by 59% among children aged 15 years or younger excluding children initiated during early infancy for primary prophylaxis (RR = 0. ...

Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients over 12 years of age with hemophilia A or B.

Not everyone with HAE needs prophylactic therapies. How C1-INH deficiency or dysfunction affects you can range in severity.

BioCryst Pharmaceuticals, Inc. today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a ...

Findings from retrospective, real-world Canadian study have shown that long-term prophylactic treatment of HAE with berotralstat is safe and effective.

In addition to the data on persisting non-medication health resource utilization among patients receiving long-term prophylaxis, the Company presented data on the global prevalence of HAE-nC1-INH ...

Patients with hereditary angioedema using modern prophylaxis had fewer attacks needing icatibant or C1-INH IV than patients on other therapies, according to a study published in The Journal of ...

Subcutaneous fitusiran prophylaxis resulted in statistically significant reductions in annualised bleeding rate in participants with haemophilia A or haemophilia B with inhibitors, with two-thirds of ...

Once-monthly prophylactic fitusiran resulted in significantly fewer bleeding episodes compared with on-demand treatment among men with hemophilia A or B with or without inhibitors, according to ...